Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 446

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

Open access
Evans, Jonathan D W, Girerd, Barbara, Montani, David, Wang, Xiao-Jian, Galiè, Nazzareno, Austin, Eric D, Elliott, Greg, Asano, Koichiro, Grünig, Ekkehard, Yan, Yi, Jing, Zhi-Cheng, Manes, Alessandra, Palazzini, Massimiliano, Wheeler, Lisa A, Nakayama, Ikue, Satoh, Toru, Eichstaedt, Christina, Hinderhofer, Katrin, Wolf, Matthias, Rosenzweig, Erika B, Chung, Wendy K, Soubrier, Florent, Simonneau, Gérald, Sitbon, Olivier, Gräf, Stefan, Kaptoge, Stephen, Di Angelantonio, Emanuele, Humbert, Marc, Morrell, Nicholas W·2016·The Lancet Respiratory Medicine

Abstract

BACKGROUND: Mutations in the gene encoding the bone morphogenetic protein receptor type II (BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH). However, the effect of BMPR2 mutations on clinical phenotype and outcomes remains uncertain. METHODS: We analysed individual participant data of 1550 patients with idiopathic, heritable, and anorexigen-associated PAH from eight cohorts that had been systematically tested for BMPR2 mutations. The primary outcome was the composite of death or lung transplantation. All-cause mortality was the secondary outcome. Hazard ratios (HRs) for death or transplantation and all-cause mortality associated with the presence of BMPR2 mutation were calculated using Cox proportional hazards models stratified by cohort. FINDINGS: Overall, 448 (29%) of 1550 patients had a BMPR2 mutation. Mutation carriers were younger at diagnosis (mean age 35·4 [SD 14·8] vs 42·0 [17·8] years), had a higher mean pulmonary artery pressure (60·5 [13·8] vs 56·4 [15·3] mm Hg) and pulmonary vascular resistance (16·6 [8·3] vs 12·9 [8·3] Wood units), and lower cardiac index (2·11 [0·69] vs 2·51 [0·92] L/min per m(2); all p<0·0001). Patients with BMPR2 mutations were less likely to respond to acute vasodilator testing (3% [10 of 380] vs 16% [147 of 907]; p<0·0001). Among the 1164 individuals with available survival data, age-adjusted and sex-adjusted HRs comparing BMPR2 mutation carriers with non-carriers were 1·42 (95% CI 1·15-1·75; p=0·0011) for the composite of death or lung transplantation and 1·27 (1·00-1·60; p=0·046) for all-cause mortality. These HRs were attenuated after adjustment for potential mediators including pulmonary vascular resistance, cardiac index, and vasoreactivity. HRs for death or transplantation and all-cause mortality associated with BMPR2 mutation were similar in men and women, but higher in patients with a younger age at diagnosis (p=0·0030 for death or transplantation, p=0·011 for all-cause mortality). INTERPRETATION: Patients with PAH and BMPR2 mutations present at a younger age with more severe disease, and are at increased risk of death, and death or transplantation, compared with those without BMPR2 mutations. FUNDING: Cambridge NIHR Biomedical Research Centre, Medical Research Council, British Heart Foundation, Assistance Publique-Hôpitaux de Paris, INSERM, Université Paris-Sud, Intermountain Research and Medical Foundation, Vanderbilt University, National Center for Advancing Translational Sciences, National Institutes of Health, National Natural Science Foundation of China, and Beijing Natural Science Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(15)00544-5

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 446

Metadata

Authors
Evans, J. D. W., Girerd, B., Montani, D., Wang, X.-J., Galiè, N., Austin, E. D., Elliott, G., Asano, K., Grünig, E., Yan, Y., Jing, Z.-C., Manes, A., Palazzini, M., Wheeler, L. A., Nakayama, I., Satoh, T., Eichstaedt, C., Hinderhofer, K., Wolf, M., Rosenzweig, E. B., Chung, W. K., Soubrier, F., Simonneau, G., Sitbon, O., Gräf, S., Kaptoge, S., Di Angelantonio, E., Humbert, M., & Morrell, N. W.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2016-02
Volume
4
Issue
2
Pages
129-137
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2253353716
Cited by
446
References
30
FWCI
7.78
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. https://app.cochat.ai/papers/10.1016/s2213-2600(15)00544-5
The paper
Evans, J. D. W., Girerd, B., Montani, D., Wang, X.-J., Galiè, N., Austin, E. D., Elliott, G., Asano, K., Grünig, E., Yan, Y., Jing, Z.-C., Manes, A., Palazzini, M., Wheeler, L. A., Nakayama, I., Satoh, T., Eichstaedt, C., Hinderhofer, K., Wolf, M., . . . Morrell, N. W. (2016). BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(15)00544-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.